Takeda Pharmaceuticals submits NDA for a new oral diabetes medication

NewsGuard 100/100 Score

Takeda Pharmaceuticals North America today announced that the company has submitted a New Drug Application (NDA) for a new oral medication that combines pioglitazone HCl and glimepiride, a sulfonylurea, to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

Takeda submitted a separate NDA for a combination of pioglitazone HCl and metformin HCl in October 2004.

ACTOS(R) (pioglitazone HCl) directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces. Glimepiride acts primarily by increasing the amount of insulin produced by the pancreas. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. The company is seeking approval to bring the medication to market in the United States.

According to the American Diabetes Association, diabetes affects an estimated 18.2 million Americans. Type 2 diabetes is the most common form, and may account for about 90 to 95 percent of all diagnosed cases of diabetes.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Landmark study sheds new light on the heterogeneity of type 2 diabetes